Evaluation of HER2/Neu gene in equivocal cases assessed by IHC in invasive breast cancer
Keywords:
HER2/Neu gene, equivocal cases, IHC, invasive breast cancerAbstract
Introduction: “HER2 is a proto-oncogene” establish on “chromosome 17q” coding tyrosine kinase receptor situated on the external membrane of the breast epithelial cells. “HER2” acts on epidermal growing element to regulator numerous cellular tasks, like propagation and differentiation of cell, cell persistence, “apoptosis, angiogenesis, migration, and metastasis”, the aim of study is showed the frequency of “Her-2/neu gene” extension in Ca. breast identified as “score 2+ by IHC” and to companion with (age, ER status and the pathological grade and stage). Method: This study was conducted over three years period from 2017-2019 and included 77 cases of invasive ductal carcinoma with equivocal Her 2 IHC results (2+). Specimen included 43 mastectomies and 34 breast core needle biopsies referred to Duhok central laboratory and Vajin private laboratory. ER status (negative versus positive) and ki67 were already done by immunohistochemistry technique for all the cases. Relation of Her2 gene status was studied in relation to different parameters including age, estrogen receptor (ER) status and ki67, for mastectomy cases, also tumor grade and pathological stage were available. Results: Cross sectional study of 77 patients with mean age (49 ± 11) years old, (26%) of patients with amplified Her2 status, (84%) of patients with positive estrogen receptor, (48%) of patients with grade II and (41.6%), with high Ki 67 (more than 20), (31.2%) of patients with T2 tumor size, (13%) of patients with N1, N2 lymph node include, finally (63.3%) of patients are below age 50 years. There is a significant association between Her2 status and grade of tumor. Conclusion: FISH is best method for evaluation of “Her-2/neu gene status” particularly for confusing patients evaluated by IHC that are no attended by correct gene strengthening in the patients with breast Ca. Amplified Her2 position related with grade III of tumor.
Downloads
References
McCormick S, Lillemoe T, Beneke J, Schrauth J, Renartz J. Her-2 assessment by Immunohistochemical analysis and fluorescence in situ hybridization. Am J Clin Pathol 2000;117:935–43.
Salmon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL, et al. Human breast cancer: correlation of relapse and survival with amplification of Her-2/neu oncogene. Science 1987;235:177–82.
Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Roka S, et al. Do we need Her-2 testing for all patients with primary breast carcinoma? Cancer 2003;98(12):2547–53.
Rosenberg CL. Polsomy 17 and Her-2 amplification: true, and unrelated. J Clin Oncol 2008;26:4856–8.
Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Anette IF, Luthardt B, et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001;19:354–63.
Panjwani P, Epari S, Karpate A, Shirsat H, Rajsekharan P, Basak R, et al. Assessment of Her-2/neu status in breast cancer using fluorescence in situ hybridization and immunohistochemistry. Indian J Med Res 2010;132:287–94.
Barett C, Magee H, O’Toole D, Daly S, Jeffers M. Amplification of the Her-2 gene in breast cancers testing 2+ weak positive by Hercep Test immunohistochemistry: false positive or false negative immunohistochemistry? J Clin Pathol 2007;60:690–3.
Ru ̈ schoff J, Nagelmeier I, Hofmann M, Henkel T, Stoss S. ErB 2 diagnostics in breast cancer – an update. Pathologie 2009;30(2):147–55.
Couturier J, Salmon A, Nicholas A, Beuzeboc P, Mouret E, Zafrani B, etal. Strong correlation between results of fluorescence in situ hybridization and immunohistochemistry for the assessment of ERB2 gene status in breast carcinoma. Mod Pathol 2000;13:1238–43.
Dolan M, Snover D. Comparison of immunohistochemistry and fluorescence in situ hybridization assessment of Her-2 status in routine practice. Am J Clin Pathol 2005;123:766–70.
Lan CH. Erb-2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ immunohistochemical analysis. Am J Clin Pathol 2005;124:97–102.
Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31 (31): 3997– 4013.
Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epider- mal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
Eswarachary V, Mohammed IG, Jayanna PK. HER2/neu testing in 432 consecutive breast cancer cases using FISH and IHC-A comparative study. J Clin Diagn Res. 2017;11(4):EC01–EC05.
Solomon JP, Dell’Aquila M, Fadare O, Hasteh F. Her2/neu status determination in breast cancer: a single institutional experience using a dual-testing approach with immunohistochemistry and fluorescence in situ hybridization. Am J Clin Pathol. 2017;147(4):432–437
Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291(16):1972–1977.
Dowsett M, Bartlett J, Ellis I, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER 2 in 426 breast carcinomas from 37 centres. J Pathol. 2003;199(4):418–423.
Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5(1):63–69.
Tse CH, Hwang HC, Goldstein LC, et al. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. J Clin Oncol. 2011;29(31):4168–4174.
Eswarachary V, Mohammed IG, Jayanna PK, Patilokaly GV, Nargund AR, Dhondalay GK, et al. HER2/neu testing in 432 consecutive breast cancer cases using FISH and IHC – A comparative study. J Clin Diagn Res 2017;11:EC01-5.
Walker RA. Use and assessment of diagnostic and predictive markers in breast pathology. Curr Diagn Pathol 2007;13:126-34
Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P. Breast J. 2005 Jul-Aug; 11(4):278-80.
Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer. Ivkovic-Kapicl T, Knezevic-Usaj S, Djilas-Ivanovic D, Panjkovic M. In Vivo. 2007 Jul-Aug; 21(4):673-8.
Siadati S, Sharbatdaran M, Nikbakhsh N, Ghaemian N. Correlation of ER, PR and HER-2/Neu with other Prognostic Factors in Infiltrating Ductal Carcinoma of Breast. Iran J Pathol. 2015;10(3):221-226.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 AVFT – Archivos Venezolanos de Farmacología y Terapéutica
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
